Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, has been hailed as a revolutionary tool in ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

A team of researchers in the United States has developed a groundbreaking cancer treatment that starves tumors by leveraging ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.